The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Date of Patent:
Nov. 25, 2014

Filed:

Mar. 29, 2010
Applicants:

Bruce Stillman, Cold Spring Harbor, NY (US);

Scott W. Lowe, Cold Spring Harbor, NY (US);

Anthony Mazurek, Cold Spring Harbor, NY (US);

Johannes Ekkehart Zuber, Cold Spring Harbor, NY (US);

Christopher Vakoc, Oyster Bay, NY (US);

Katherine Mcjunkin, Cold Spring Harbor, NY (US);

Inventors:

Bruce Stillman, Cold Spring Harbor, NY (US);

Scott W. Lowe, Cold Spring Harbor, NY (US);

Anthony Mazurek, Cold Spring Harbor, NY (US);

Johannes Ekkehart Zuber, Cold Spring Harbor, NY (US);

Christopher Vakoc, Oyster Bay, NY (US);

Katherine McJunkin, Cold Spring Harbor, NY (US);

Assignee:

Cold Spring Harbor Laboratory, Cold Spring Harbor, NY (US);

Attorney:
Primary Examiner:
Int. Cl.
CPC ...
C12N 15/11 (2006.01); A01K 67/027 (2006.01);
U.S. Cl.
CPC ...
A01K 67/0271 (2013.01); A01K 2227/105 (2013.01); C12N 15/111 (2013.01); C12N 2310/14 (2013.01); C12N 2310/531 (2013.01); C12N 2799/027 (2013.01); C12N 2840/203 (2013.01); C12N 2830/003 (2013.01); A01K 2207/12 (2013.01); A01K 2267/0393 (2013.01); A01K 2267/0331 (2013.01); A01K 2207/05 (2013.01); C12N 2330/51 (2013.01); C12N 2320/11 (2013.01);
Abstract

Provided is a mosaic mouse model for use in determining the potency of an shRNA in vivo for reducing survival of cancer cells of chemotherapy-resistant leukemia. The syngeneic mouse recipient is transplanted with tet-on competent leukemia cells carrying a bicistronic nucleic acid construct comprising a promoter operably linked to a fusion gene associated with chemotherapy-resistant leukemia, and a sequence encoding a reverse tet-transactivator protein, such that both coding sequences are co-expressed from the promoter. Also provided are methods of treating soft tissue cancers.


Find Patent Forward Citations

Loading…